ArticleJournal of thoracic disease2026
Increased rates of surgical resection of early-stage small cell lung cancer in a single-institution cohort.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- NLRC4 and NLRP3 in tissues as potential biomarkers for the diagnosis of non-small cell lung cancer in pulmonary tuberculosis.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Increasing chest imaging utilization, including for screening, identifies more non-small cell lung cancer (NSCLC) at earlier stages. We suspected that a parallel increase in early detection and resection of small cell lung cancer (SCLC) was also occurring. We therefore reviewed our institutional experience to explore trends in surgically resected SCLC frequency and outcomes. Methods: A single-institution, retrospective review was performed of all SCLC cases resected between 2000-2022. We evaluated demographics, oncologic characteristics, overall survival (OS), and disease-free survival (DFS). Results: Among 30 patients with resected SCLC, the majority underwent lobectomy (73%) and only 37% were known to have SCLC preoperatively. The frequency of resections increased over time with almost half (47%) occurring in the last four study years (2019-2022). This increase in SCLC resections coincided with increasing lung cancer screening (LCS) volume, with no change in thoracic surgical case volume. The 2019-2022 cohort was predominantly clinical stage I (86%) compared to 56% pre-2019 (I Conclusions: The number of surgically resected SCLC patients at our institution has increased in recent years, as has the proportion of screen-detected and clinical stage I cases, alongside rising LCS volume. This may be an early signal of a broader trend toward increasing diagnosis of limited stage SCLC eligible for resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.